Is Bioxytran, Inc. (BIXT) a Buy, Sell, or Hold?
OTC : BIXT
Bioxytran, Inc. — News
$0.0238 USD
$0.0 (0.1%)
- Volume
- 43.44K
- Average Volume
- 48.1K
- Market Capitalization
- $2.72M
- P/E Ratio
- -0.90
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.10
- Year Low
- $0.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.09
| Source | Headline |
|---|---|
|
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25. The book “Physiological Mapping of the Cerebral Cortex in Neuropathology” (978-3-032-13018-1) by Springer, was authored independently by Dr. Mayevsky, and the book introduces the concept of “Physiological Mapping,” a unique methodology designed to monitor tissue metabolism and oxygenation in vivo and in real-time. globenewswire.com - 2026-05-29 08:03:00 |
|
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a new scientific book by internationally recognized physiologist and researcher Avraham Mayevsky that may provide scientific perspectives relevant to future evaluation methods for oxygen therapeutics such as BXT-25. globenewswire.com - 2026-05-29 08:03:00 |
